Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just don't see the volume to justify these rumors.
Well, my limit sell order is in for $1.00 so if anyone is interested in taking me out, be my guest. LOL.
Oh and one more thing, I have lots available at that price.
Guess it is hard to think that big whilst we are sitting sub 2 cents. LOL!
Possible? Not really sure. Reverse split? Hope not. Anyone have any color to add? From small seeds do big trees grow.
All that I ask is a decimal place move two to the right.
baseman,
agree with your technical analysis and see the writing on the wall as well. big pops don't usually just happen over night. bottom line, a story is being told here and we are in the prelude or chapter 1. this is a good story and in time it'll be told.
many folks getting set here and lots of large holders are not looking for a penny or two to unload, imo.
personally, i'm a position trader and made buys at .02, .04, .05, .055 & .06. not based on anything other than continued due diligence where the story seems to be getting better.
not sure whether this is right or not, but i'd rather buy a stock on the way up rather than chase it down. what do you think of this strategy? it has worked for me in the past.
my bases are loaded at the moment. might continue to add, we'll see how this unfolds. my longer-term target is $1.00.
it's a long way off, most definitely, but i'm very patient.
Could you elaborate a bit on what exactly you mean by TWO Indian Gaming Commission opinions? I have read ONE on NGIC.gov board. I'd be interested to read another.
Thanks!
SOYO - relevant...
http://www.woot.com/
this is a steal, no?
PGLA - Progen Pharma - $3.15
Okey dokey folks, I'm back on my Progen rant.
This one has crashed pretty hard from their last data release.
Back in April, the FDA gave the go ahead to SKIP part B of Phase 2 and go right to Phase 3 trials for their compound - PI-88. They did a capital raise in the USA and now have enough $$$ to take the drug straight to commercialization. The data were good! And, based on forward-looking events we've got only a couple weeks left in Q3 before they release another indication - NSCLC Lung Cancer trial data.
I'd sock a few away at this level as the company has never been in a stronger position. And, the uncertainty of whether the drug works is gone. It does work!
Still a tiny float overall ~59MM with only about 5MM in the USA.
SAC Capital is the largest holder of the stock in the USA and they now have for the FIRST time ever, an insto following. The pieces are starting to fall into place. I still see $20-$25 in the cards....sooner than later.
Ask any questions that you might have......I'm the resident expert in this Aussie biotech!
See you at the top (eventually).
:) Rick
Thanks Hailrdskins!
So one had to buy on or before 8/31 to get the $$$, right?
It's trading ex, now...?
Thanks again!
:) Rick
Complicated dividend question:
http://biz.yahoo.com/prnews/070831/ukf009.html?.v=86
Guys, I know the whole ex-date thing gets overblown here.
But in this case, with the foreign stock, the holiday Monday, etc. I'll admit it, I'm still confused!
Appreciate you guys' insight.
:) Rick
There was a mention awhile back about the .14 cent monthly dividend stocks (RMH, RMA, RSF, RHY). I put them all on my watch list, thanks.
But, someone here had mentioned the impact of the yield curve on them. I'm curious if you guys could elaborate a bit more. Trying to learn. Wondering if the payout ratio would go up or down once the yield curve changes? Looks like a good way to get some great income....if it'll continue. Thanks in advance!
E*Trade screw up........? Nah, can't be. LOL.
BDEV - PR (apologies if this was posted yesterday - didn't see it.) This came up under the symbol in etrade.
Data Warehouse Solutions made practical by SingleVision software from Business Development Solutions
May 15, 2007 10:35:23 (ET)
MOUNT LAUREL, N.J., May 15, 2007 (BUSINESS WIRE) -- Effective data warehouse solutions are now available to many more organizations with data management issues by the introduction of SingleVision(R) software from Business Development Solutions, Inc. SingleVision provides a single searchable universe of coordinated data from separate sources with decreased set-up times, learning curves, and costs.
"SingleVision's data warehouse solution has a sophisticated matching and linking process enabling organizations to manage data on an on-going basis even as the original data sources are being updated and even without having to clean-up data. This is a great advantage over traditional merge/purge, data importing, and other matching tools," says Robert Bloom, President of Business Development Solutions. "The ease of use and cost effectiveness make SingleVision a viable customer data integration and data management option, whether managing 20,000 contacts in one database with a duplicate record issue or 2 million records in multiple databases needed for viewing, analysis, list building, and file maintenance of several distinct data sources."
Utilizing the SingleVision application, data warehouse objectives can be accomplished in a relatively short time frame and for a reasonable investment. Representatives can see a single view of an account's information from different departments such as sales, financial, and customer service; from external marketing files like D&B(R) and infoUSA(R); and from other databases. Reports from the data warehouse can be generated utilizing business intelligence from multiple data sources. Data management issues can be identified and resolved.
About Business Development Solutions, Inc.:
Since 1991, Business Development Solutions has been focused on helping marketers of all sizes identify, analyze, and serve their customers and prospects more effectively. With this experience, we have developed the advanced customer data integration matching and linking processes of SingleVision to maximize the value and accessibility of the data our client companies use and maintain.
D&B(R) is a registered trademark of The Dun & Bradstreet Corporation
InfoUSA(R) is a registered trademark of infoUSA Inc.
Optimized by Newsforce
SOURCE: Business Development Solutions, Inc.
Steven Kahn
Business Development Solutions, Inc.
856-787-1500
info@bdsdatabase.com
http://www.bdsdatabase.com
PGLA - Progen Pharmaceuticals
FYI - Today's shares (up to the ex-date) contain a 1 for 9 rights offering with an exercise price of $4.75. And, of those bonus rights you will get a 1 for 2 option that is exercisable @ $6.95USD expiring in 2010. Requires a calculator for this exercise. They will be rounding up fractional rights and rounding down options.
BTW, They now have 100% ownership of their intellectual property and $100MM in the bank.
From little things, big things grow. Remember DNDN's capital raise below $5 back in November. Ahhh, hindsight.
:) Rick
MAMG - you guys see the news....?
Comment??
3V Cap Wants Representation On Universal Power's Board >UPG
Dow Jones Newswires - April 26, 2007 12:48 PM ET
Symbol Last Chg
UPG Trade 5.15 +0.53
Real time quote.
DOW JONES NEWSWIRES
3V Capital Management LLC said Wednesday that it recently sent a letter to Universal Power Group Inc. (UPG) asking for representation on the company's board.
According to a Schedule 13D filed with the Securities and Exchange Commission, 3V Capital holds a 12.6% stake in Universal Power, which provides third-party logistics and supply chain management services.
In the letter, sent to Universal Power on April 19, 3V Capital also requested a meeting with the company's board to discuss its views with regard to creating shareholder value, and improving the market's impression of the company's intrinsic value. It also said it wants to work "constructively and consensually" with Universal Power's executive management team and board to help "refine and better communicate" the company's business strategy and operating plan to the investor community.
The Greenwich, Conn.-based investment adviser said it may hold discussions with third parties, or make proposals regarding potential changes in the company's operations, management or capital structure as a means of enhancing shareholder value. Such suggestions may include selling all or a portion of the company, changing its operating or marketing strategies, or adopting or not adopting certain types of anti-takeover measures, as well as restructuring the company's capitalization or dividend policy.
Universal Power's shares were recently trading at $4.58 each, off 4 cents from Wednesday's close.
-Brian Coyle, Dow Jones Newswires; 202-862-3545
> Dow Jones Newswires
04-26-07 1039ET
Copyright (c) 2007 Dow Jones & Company, Inc.
Guys, look at UPG (Universal Power Group).
Seems they might be the target of a takeover based on the today's news. And, remember that ZNCM (Zunicom) owns like 2,000,000 shares of UPG.
Might be the reason for the perking of ZNCM today???
Target is still $20.
PGLA - we're not even to the center of the lollie yet.
Hold your shares tightly. Lots more news and events in the cooker. Remember, the drug works! Rights offering coming for existing shareholders. You have to be 'in' to win.
PGLA gonna pull a DNDN-type move pretty soon.
You've all had plenty of time to accumulate prior to 48 week data release on Saturday, April 14th. I expect that we will continue to build up to this date and thereafter as the story continues to unfold. 5 Int'l cancer trials. Lots of good stuff. PI-88 is working and will soon have a sexy scientific name.
ZNCM a hold for the time being then Steve?
I'm still holding but haven't gotten divvy from ETURD yet.
I'm confident it'll come.....but not too happy with the move down in ZNCM post divvy. There's always next week....
They are Hudson Securities the Market Maker in case you don't recall. And, they are always on-time with filings, etc. acting like a real company that is growing. would like to see them at a few bucks.
HDHL - SSP or Jim, any comment on the recently filed SB-2.
What do you make of it...?
Appreciate anyone's input.
yep. that's my plan too. a la NEGI.
ZNCM - GONNA TRADE EX TODAY?
If so, how do you guys view the current bid/ask?
Good or bad, in your opinion???
yep, maybe 109,940 shares worth of folks......?
LOL.
i listened to that post too. knew it would prolly happen.
still holding all shares from pre-split + divvy cash!
in hindsight, should've used the divvy to buy more!
<laughing now>
NEGI - creeping.......
PGLA - Progen invited to present their 48 week data at the following upcoming annual international cancer conferences:
European Association for the Study of the Liver - April 11th - 15th in Barcelona, Spain.
American Association for Cancer Research - April 14th - 18th in Los Angeles.
You'll recall what the 30 week data release did for the stock price back in December.
Right now, parity is at $6.75 w/ $AUD....so we still have some catching up to do.
As my 4 year old so perfectly says it "ah pickle chips, dad."
MAMG - News!
LOL. I almost fell outta my chair.
We're all still screwed, right?
PGLA - Hope you're in.....this just released 'after the bell' last night. The data must be really good to go through all this effort.
PI-88 Data to be Presented at Key International Conferences
Brisbane, Australia. 12 March 2007: Progen Industries Limited (ASX: PGL; NASDAQ: PGLA) is pleased to announce that its PI-88 Phase II liver cancer data has been accepted for late breaking news presentation by the European Association for the Study of the Liver (EASL). Progen will also be presenting the results of this liver cancer trial at the American Association for Cancer Research (AACR) Annual Meeting 2007.
In expectation of having final data fully analysed and ready for disclosure, Progen is planning for Professor PJ Chen, Principal Investigator of this trial, to present the 48 week data for all 172 patients that were recruited to this multi-site Phase II clinical trial. This presentation will take place on Saturday 14 April 2007 at the 42nd EASL Annual Meeting, which is to be held in Barcelona, Spain from April 11-15, 2007.
Dr. Anand Gautam, Progen’s VP of Discovery Research, will be presenting results at the AACR Annual Meeting 2007, which will be held in Los Angeles, U.S, from April 14-18, 2007.
About Progen: Progen Industries Limited is an Australian based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals for the treatment of cancer and other serious diseases.
NEGI - lots of buys this past week at the ask of $4.75.
big blocks. someone's accumulating.
they are a shell now w/ $53MM in the bank.
NEGI + DIVY = POSI - LOL
Anyone have any comment or perspective?
I'm still holding....targets?
sue,
you didn't think that 'stated income' & 'stated assets' and 'no income verification' coupled with a sub 600 credit score was ever gonna be a problem...?
LOLOL.
NEGI - some big trades at the ask....
setting up for a push through $5.00??
interesting.....comments?
NEGI - perking...
NEGI - lookin' schweeeet!
NEGI - bid building.
koolmc, can you reply with a little more detail to that post?
50 vs. 70 rsi would be what pps?
thanks!
PGLA - buy signal.
Not too many days left prior to the General Meeting....March 16th.
Tends to be halted the day before as well....so the days below $6 are numbered.
They will most probably announce one or more of the following:
1. Final Liver Data - you saw what the preliminary data did to the share price.
2. Regional Partner for PI-88.
3. Another indication's results. (There are currently 4 on-going trials)
4. Right's offering for existing shareholders.
See you at $12.00